BioVie Inc.

We’re thrilled to welcome Ugochi Owo, founder and CEO of Flindel, as a strategic advisor to BioVie. Ugochi brings an entrepreneurial mindset, a deep personal connection to the Alzheimer’s community, and a unique ability to build meaningful networks. Her passion for innovation and connecting people aligns powerfully with our mission to address some of today’s pressing unmet medical needs – including treatments for Alzheimer’s disease, Parkinson’s disease and long COVID – by targeting neuroinflammation at its source. Along with strategic know-how, Ugochi is a dedicated philanthropist, working with World Vision to provide quality education and resources for underprivileged children and to bridge socioeconomic gaps.   Her insight and advocacy will be invaluable as we continue advancing therapies that have the potential to change lives. Welcome to the team, Ugochi!   #Neurology #AlzheimersDisease #ParkinsonsDisease #LongCOVID

We have been investigating our lead compound bezisterim (NE3107) in diseases of aging, including both Parkinson’s disease (PD) and Alzheimer’s disease (AD). We will soon be enrolling a Phase 2 trial in long COVID, because we recognized a shared pathology across these disorders: inflammation in the brain. Research continues to link neuroinflammation to the persistent cognitive issues of long COVID. These symptoms, such as “brain fog,” memory loss and fatigue, are similar to symptoms seen with other neurodegenerative disorders – leading to growing concerns from experts that long COVID may serve as a risk factor or accelerator. The Wall Street Journal interviewed leading experts and patients about this concept in a recent article: https://lnkd.in/eDPWPsqr Bezisterim targets key underlying mechanisms of neuroinflammation, and has demonstrated the ability to reduce chronic neuroinflammatory symptoms in AD and PD; our hypothesis is that this mechanism may be able to address neurological symptoms of cognitive dysfunction and fatigue in long COVID. Watch the replay of our KOL event from last week featuring Lindsay McAlpine MD (Yale University) who discussed in more detail the role of neuroinflammation in long COVID, and our ADDRESS-LC clinical trial in long COVID: https://lnkd.in/e5Qmsi4U #LongCOVID #Neuroscience #AlzheimersDisease #Aging #ParkinsonsDisease

Enrollment is now open for our Phase 2 SUNRISE-PD trial evaluating bezisterim for the treatment of motor and non-motor symptoms in patients with #Parkinsons disease who haven’t been treated with carbidopa/levodopa. The first patient in the trial has been enrolled, and topline data are expected in late 2025 or early 2026. Compelling evidence implicates inflammation and insulin resistance in the initiation and progression of the disease – likely both due to their respective roles in dopamine dysfunction in the brain and neurodegeneration. By targeting these two underlying mechanisms, bezisterim may offer a novel therapeutic approach distinct from current treatments. Read our press release to learn more: https://lnkd.in/eJ-af7G5 $BIVI #ParkinsonsResearch #ClinicalTrials #Inflammation

We're thrilled to welcome Tim Gardner, De Armond Chair in Neuroengineering at the University of Oregon and co-founder of Neuralink, as an advisor to BioVie. Tim brings deep expertise in brain function and systems neuroscience that will be invaluable as we continue the development of bezisterim, our investigational therapy targeting neuroinflammation and insulin resistance, in Alzheimer’s disease, Parkinson’s disease, and the neurological symptoms of long COVID.   His perspective will help us explore how reducing inflammation and modulating insulin in the brain may offer new hope for patients facing these debilitating conditions. We’re excited to have Tim’s insights guiding our efforts at the intersection of innovation and neuroscience.   #Neuroscience #Inflammation #AlzheimersResearch #ParkinsonsResearch #LongCOVID

Today, on World Parkinson’s Day, we stand in solidarity with the more than 10 million people worldwide living with Parkinson’s disease—an incredibly resilient community that continues to face daily challenges due to the limitations of current treatment options. While today is part of a broader month of awareness, it carries a unique significance: a global moment to reflect on the urgent unmet needs in Parkinson’s care and the importance of advancing research that looks beyond traditional treatment pathways. We’re proud to partner with leading voices in the patient community like Davis Phinney Foundation, Parkinson's Foundation and The Michael J. Fox Foundation for Parkinson's Research - their work to improve quality of life for those living with Parkinson’s is deeply aligned with our own goals, especially through our ongoing SUNRISE-PD trial, which explores a new approach to treatment by targeting neuroinflammation and insulin resistance. At BioVie, we are committed to helping expand the possibilities for patients and grateful to be part of a community working together to change the future of Parkinson’s disease. #WorldParkinsonsDay #ParkinsonsAwareness #Neuroinflammation #ClinicalTrials #ParkinsonsResearch

Did you miss our virtual investor event featuring key opinion leader (KOL) Lindsay McAlpine MD, Yale University? Watch the replay to learn more about the unmet need and current treatment landscape for #longCOVID. The discussion also covered the evidence implicating chronic neuroinflammation in the persistence of long COVID symptoms. Access the recording here: https://lnkd.in/e5Qmsi4U $BIVI #Inflammation #COVID #CovidResearch

We’re thrilled to welcome Dr. Zaldy Tan, a nationally recognized Alzheimer’s disease expert and Director of Cedars-Sinai’s Memory & Healthy Aging Program, as an advisor to BioVie. Dr. Tan’s deep clinical and research expertise will help advance our mission to illuminate and validate new therapeutic approaches in Alzheimer’s disease—beyond the traditional focus on amyloid beta plaques and tau protein tangles. Our science is centered in emerging evidence that implicates both neuroinflammation and insulin resistance in the onset and progression of Alzheimer’s. With Dr. Tan’s guidance, we’re excited to continue building awareness around these pathways and the potential impact of our investigational therapy, bezisterim, to offer a new approach to treating this devastating neurodegenerative condition. #AlzheimersDisease #Neuroinflammation #ClinicalResearch #Neuroscience #BeyondAmyloid

Today is World Health Day. 🌏 Someone new is diagnosed with Parkinson’s disease in the U.S. every 6 minutes. At the Parkinson’s Foundation, we’re dedicated to making life better for the PD community by improving care and advancing research toward a cure. Visit Parkinson.org/Resources to explore information and programs that can improve the lives of people living with Parkinson’s disease and those who love them.

At BioVie Inc., we stand alongside the 10 million people worldwide living with Parkinson’s disease (PD)—a progressive neurodegenerative disorder that impacts movement, cognition, and quality of life. This month is about awareness, education, and hope. While existing therapies can help manage symptoms, they do not address the complex biological factors contributing to disease progression – and we believe there’s more to be done. Neuroinflammation and insulin resistance are increasingly recognized as key drivers of PD onset and progression, and our team is committed to pioneering a differentiated approach to treatment that addresses these underlying mechanisms. 💙 To all patients, families, caregivers, and advocates—you are not alone. Your strength fuels our mission to advance science and improve lives. #ParkinsonsAwarenessMonth #ParkinsonsResearch #HopeForPD #Neuroinflammation #InsulinResistance

Join us in two weeks for a virtual investor event featuring key opinion leader (KOL) Lindsay McAlpine MD, Yale University, who will join company management to discuss the unmet need and current treatment landscape for #longCOVID. The discussion will also cover the evidence implicating chronic neuroinflammation in the persistence of long COVID symptoms. Learn more about the event and register here: https://lnkd.in/eBBkZNFx $BIVI #Inflammation #COVID #CovidResearch